Molekulargenetisches Labor
Zentrum für Nephrologie und Stoffwechsel
Die kombinierte familiäre Hyperlipämie mit VLDL-Überproduktion beinhalted Fettstoffwechselstörungen, bei denen die Mutationen zu einer Bildung und Sekretion von VLDL in das Plasma führen.
| 1. |
Pajukanta P et al. (2004) Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). [^] |
| 2. |
Coon H et al. (2005) Upstream stimulatory factor 1 associated with familial combined hyperlipidemia, LDL cholesterol, and triglycerides. [^] |
| 3. |
Aouizerat BE et al. (1999) A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. [^] |
| 4. |
Bodnar JS et al. (2002) Positional cloning of the combined hyperlipidemia gene Hyplip1. [^] |
| 5. |
Pajukanta P et al. (1998) Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. [^] |
| 6. |
Castellani LW et al. (1998) Mapping a gene for combined hyperlipidaemia in a mutant mouse strain. [^] |
| 7. |
Pei W et al. (2000) Support for linkage of familial combined hyperlipidemia to chromosome 1q21-q23 in Chinese and German families. [^] |
| 8. |
Pajukanta P et al. (2001) Fine mapping of Hyplip1 and the human homolog, a potential locus for FCHL. [^] |
| 9. |
Huertas-Vázquez A et al. (2004) Contribution of chromosome 1q21-q23 to familial combined hyperlipidemia in Mexican families. [^] |
| 10. |
OMIM.ORG article Omim 602491 [^] |
 |
Copyright © 2005-2020 Zentrum für Nephrologie und Stoffwechsel, Dr. Mato Nagel Albert-Schweitzer-Ring 32, D-02943 Weißwasser, Deutschland, Tel.: +49-3576-287922, Fax: +49-3576-287944 Seitenüberblick | Webmail | Haftungsausschluss | Datenschutz |
